20th July 2023
Celix Pharma announces the launch of Ranolazine Prolonged-release (PR) tablets
Celix Pharma is pleased to announce the launch of Ranolazine Celix Prolonged-release (PR) tablets post the loss of exclusivity for Ranexa® in the UK. Ranolazine 375mg, 500mg and 750mg PR tablets are supplied in blister packs containing 60 tablets.
Ranolazine Celix is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Ranolazine is thought to work by reducing the flow of calcium ions into the heart muscle cells. Calcium ions normally cause the heart muscle to contract. By reducing the flow of calcium into the cells, ranolazine is thought to help the heart to relax, improving blood flow to the heart muscle and relieving the symptoms of angina pectoris (chest pain) (1).
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Ranolazine is an important addition to our portfolio of patent expiry linked launches. Brilliant team effort to bring this product to market in a very short space of time between regulatory filing and launch.”
Shantreddy, Co-founder & COO added, “I am very pleased with this launch of Ranolazine. It is another example of successful collaboration between Celix and our partners, as we had to overcome several hurdles along the way with this highly time-sensitive project. I would like to thank our partners for their trust and support in making this launch possible.”
Source:
1 https://www.ema.europa.eu/en/documents/overview/ranexa-epar-summary-public_en.pdf